GLYC Overview
Upcoming Projects (GLYC)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (GLYC)
-
Discussing GlycoMimetics' Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML)
Ticker: GLYC
Executed On: Mar 20, 2024 at 06:30 PM EDT -
Discussing uproleselan potential in relapsed/refractory AML and the ongoing phase 3 study
Ticker: GLYC
Executed On: Feb 15, 2024 at 11:30 AM EST
Upcoming & Overdue Catalysts (GLYC)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (GLYC)
-
GlycoMimetics (GLYC) Announces Dosing of First Patient in Phase I Trial of GMI-1271 in Multiple Myeloma
Ticker: GLYC
Occurred on: Sep 14, 2016 -
GlycoMimetics Set to Initiate Phase 1 Trials for GMI-1359 After Promising Data from Preclinical Trials
Ticker: GLYC
Occurred on: Sep 06, 2016 -
GlycoMimetics to Initiate GMI-1271 Myeloma Trials in Mid-2016
Ticker: GLYC
Occurred on: Jun 28, 2016 -
GlycoMimetics Announces Pricing of Public Offering of Common Stock
Ticker: GLYC
Occurred on: Jun 17, 2016 -
GlycoMimetics' GMI-1271 Receives FDA Fast Track Designation for Treatment of Acute Myeloid Leukemia
Ticker: GLYC
Occurred on: Jun 13, 2016 -
GlycoMimetics to Release Phase 1/2 Data for GMI-1271 for Reducing Chemotherapy Resistance and Enriching T-Cells
Ticker: GLYC
Occurred on: Jun 10, 2016 -
GlycoMimetics' GMI-1271 Yields High Remission Rates and Favorable Tolerability in Phase 1 Portion of Phase 1/2 Clinical Trial for AML
Ticker: GLYC
Occurred on: Jun 10, 2016 -
GlycoMimetics to Present New Preclinical Data on GMI-1359 Dual Antagonist
Ticker: GLYC
Occurred on: Apr 16, 2016 -
GlycoMimetics Releases Initial Clinical Data from Phase 1 GMI-1271 Study of Patients with Acute Myeloid Leukemia
Ticker: GLYC
Occurred on: Mar 02, 2016
Strategic Initiatives (GLYC)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
